Results for tag: "Triptorelin"

Triptorelin is a synthetic decapeptide agonist of the gonadotropin-releasing hormone (GnRH) receptor used in the treatment of prostate cancer. It is administered as a subcutaneous injection and works by reducing the production of testosterone, which can slow the growth of prostate cancer cells. Triptorelin is used in combination with other treatments such as radiation therapy and chemotherapy. It is also used to reduce the risk of prostate cancer recurrence after surgery. Triptorelin is a relatively new drug in the prostate cancer market, but it has been gaining traction due to its effectiveness and convenience. It is generally well-tolerated and has fewer side effects than other treatments. Some companies in the Triptorelin market include AbbVie, Astellas Pharma, Endo Pharmaceuticals, Ferring Pharmaceuticals, and Teva Pharmaceuticals. Show Less Read more